Photo Credit: PixabayA cure for the blood-clotting disorder hemophilia B is listed at a cost for $3.5 million per dose, as reported by the Food and Drug Administration. RELATED STORIES: Abbott Baby Formula Plant Reopens After Approval From FDAAdvertisementThe U.S. Food and Drug Administration approved Hemgenix last Tuesday, a gene-therapy treatment to help adults with hemophilia B, a genetic disorder. The product was first developed by Dutch biotechnology company UniQuire and CSL Behring paid $450 million for the licensing. However, the high price tag will deter patients since hemophilia B affects about 6,000 people in the United States and only 15 percent will be eligible for the drug. Despite the high price tag for the newly approved gene therapy for hemophilia B, Hemgenix, the budget impact for payers will be manageable.

Source: Forbes December 03, 2022 12:32 UTC